Carregant...

CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma

Targeting disialoganglioside (GD2) on neuroblastoma (NB) with T cells expressing a first-generation chimeric antigen receptor (CAR) was safe, but the cells had poor expansion and long-term persistence. We developed a third-generation GD2-CAR (GD2-CAR3) and hypothesized that GD2-CAR3 T cells (CARTs)...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Mol Ther
Autors principals: Heczey, Andras, Louis, Chrystal U., Savoldo, Barbara, Dakhova, Olga, Durett, April, Grilley, Bambi, Liu, Hao, Wu, Mengfeng F., Mei, Zhuyong, Gee, Adrian, Mehta, Birju, Zhang, Huimin, Mahmood, Nadia, Tashiro, Haruko, Heslop, Helen E., Dotti, Gianpietro, Rooney, Cliona M., Brenner, Malcolm K.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Gene & Cell Therapy 2017
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5589058/
https://ncbi.nlm.nih.gov/pubmed/28602436
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ymthe.2017.05.012
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!